ArticleWorld journal of microbiology & biotechnology2025
High-throughput screening identifies novel chemical scaffolds targeting Leishmania donovani parasites.
Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Coumarin derivatives as new chemotype targeting leishmanial sterol biosynthesis pathway proteins: an integrated in vitro, mechanistic, and in silico evaluation.World journal of microbiology & biotechnology · 2026Article
- Deciphering the potentiality of Andrographolide derivatives against Pseudomonas aeruginosa: in vitro analysis and mechanistic insights.World journal of microbiology & biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
High-throughput screening (HTS) is one of the critical strategies that can accelerate the process of drug discovery by exploring small drug-like molecule libraries. HTS noticeably contributes to the identification of potential hits using various automation tools and biological assays. Leishmaniasis, a neglected tropical disease, is one of the most deadly protozoan parasitic infections causing significant global burden in certain poverty-stricken countries. Given the paucity of effective chemotherapeutic agents available for the treatment of this life-threatening infection, the discovery of novel leishmanicidal scaffolds through innovative strategies is pivotal to combating this parasitic disease. In the present study, we have employed the HTS strategy to scrutinize 10,000 drug-like molecules from the in-house ChemDiv library to identify potent hits against Leishmania donovani. Noticeably, 99 molecules showed > 80% inhibitory effect against the L. donovani parasites at 50 µM concentration, and among them, four molecules displayed a 50% inhibitory concentration (IC
Indexed as
Identifiers
40610818What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.